Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitotic Kinesin Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Eg5/KIF11 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIF11 Recombinant Protein (WT / Mutant Panel) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for ATPase assays. |
View KIF11 Products |
| Gene Delivery | KIF11 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and monoastral spindle phenotype rescue assays. |
View KIF11 Products |
| Benchmark Ab | Anti-KIF11 Recombinant Antibody Recombinant positive control for immunofluorescence (IF) and Western Blotting (WB). |
View KIF11 Products |
| Validator | KIF11 siRNA Set For target knockdown verification and phenotypic correlation. |
View KIF11 Products |
| Related Target A | KIF15 (Kinesin-12) Bypasses Eg5 inhibition; critical target for overcoming Eg5 inhibitor resistance. |
View KIF15 Products |
| Related Target B | TPX2 Spindle assembly factor that spatially regulates Eg5; key node in mitotic spindle architecture. |
View TPX2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Drug-Resistant Mutation Screening (e.g., D130V, A133D) | Sequence-verified mutant recombinant proteins available with >95% purity |
| Kinesin Subfamily Counter-Screening (Off-target profiling) | Homolog panel proteins (KIF15, KIF1C, KIF2C) strictly verified by mass spectrometry |
| Lack of Controls | Clinical benchmark antibodies and validated siRNA included in the workflow |
| False Positives in Phenotypic Assays | Lentivirus-mediated rescue systems to confirm target-specific mitotic arrest |
Live Eg5/KIF11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Eg5 (Kinesin Family Member 11, KIF11) remains a highly attractive strategy in oncology due to its exclusive role in mitotic spindle bipolarity. While early small-molecule Kinesin Spindle Protein (KSP) inhibitors like ispinesib and filanesib demonstrated robust preclinical efficacy, clinical translation was historically limited by systemic neutropenia and rapid development of drug resistance.
The race for Eg5/KIF11 therapeutics is intensifying, with major players shifting focus from traditional systemic small molecules to targeted delivery systems (such as ADCs and nanoparticle formulations) and combination regimens. As first-generation therapies reach the clinic, the next wave of R&D is targeting drug-resistant mutations and exploiting synthetic lethal relationships with other mitotic regulators.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (KSPi) | Cytokinetics, Eli Lilly, Array BioPharma | Hematological Malignancies (MM, AML), Solid Tumors | Selectivity Assay (Need Mutant vs WT Proteins to screen loop 5 binding pocket mutations) |
| Targeted Nanoparticles / ADCs | Academic Consortia, Biotech Startups | Ovarian Cancer, Triple-Negative Breast Cancer (TNBC) | Internalization & Release Assays (Need high-purity recombinant proteins for target binding validation) |
| Combination Therapies (with KIF15i) | Inhibitor Developers | Refractory Solid Tumors | Bypass Pathway Validation (Need KIF15 and TPX2 counter-screening panels) |